Trial Profile
PAZOPANIB Efficacy and Tolerance in Desmoids Tumors : Phase 2 Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Methotrexate; Vinblastine
- Indications Fibroma
- Focus Therapeutic Use
- Acronyms DESMOPAZ
- 19 Jul 2019 Results published in the Lancet Oncology
- 19 Jun 2018 New trial record
- 05 Jun 2018 Primary endpoint (Efficacy evaluation in terms of non progression rate at 6 months of treatment methotrexate-vinblastine) has been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.